At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
pemetrexed +1 moredrug
Likely dose
pemetrexed 500 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients
In Brief
A Phase 2 clinical trial evaluating pemetrexed and carboplatin for Non Small Cell Lung Cancer. Completed, enrolled 62 participants across 7 sites.
Detailed Summary
A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2006
Enrollment StartAug 2006
Primary CompletionNov 2008
Study CompletionNov 2009
TodayJul 2026
First PostedJul 11, 2006
Enrollment StartAug 1, 2006
Primary CompletionNov 1, 2008
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.0 years ago
Interventions
pemetrexeddrug
500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles
carboplatindrug
Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles